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Abstract. Following our discovery of a fragment from the repeat domain of tau protein as a structural constituent of the
PHF-core in Alzheimer’s disease (AD), we developed an assay that captured several key features of the aggregation process.
Tau-tau binding through the core tau fragment could be blocked by the same diaminophenothiazines found to dissolve
proteolytically stable PHFs isolated from AD brain. We found that the PHF-core tau fragment is inherently capable of auto-
catalytic self-propagation in vitro, or “prion-like processing”, that has now been demonstrated for several neurodegenerative
disorders. Here we review the findings that led to the first clinical trials to test tau aggregation inhibitor therapy in AD as a
way to block this cascade. Although further trials are still needed, the results to date suggest that a treatment targeting the
prion-like processing of tau protein may have a role in both prevention and treatment of AD.
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tau protein
“PRION-LIKE” PROCESSING OF TAU
PROTEIN
We first used the term “prion-like” in connection
with the pathological processing of tau protein as
a basis for developing a treatment in Alzheimer’s
disease (AD) exactly 20 years ago [1]. This was
the title of an extensive review summarizing our
work over the preceding 12 years. Since then, the
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concept of prion-like processing of proteins to form
characteristic pathological aggregates has come to
be understood as a general molecular mechanism
underlying a number of progressive neurodegener-
ative disorders [2–6]. For us, the idea arose from
attempts to understand the surprising ability of a fam-
ily of molecules of the diaminophenothiazine class
to reverse the proteolytic stability of the otherwise
highly resistant tau polymers, known as paired helical
filaments (PHFs), isolated from the brains of patients
dying with AD. We had found [7, 8] that it was pos-
sible to prepare an essentially pure preparation of
PHFs from AD brain tissues using a combination of
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differential centrifugation and digestion with a broad
spectrum exoprotease (Pronase). The resulting PHFs
retained their typical structural characteristics apart
from the loss of a proteolytically susceptible fuzzy
outer coat [9, 10]. Treatment of these preparations
with formic acid released a 10–12 kDa fragment of
tau protein restricted to the repeat domain of the
molecule [8], thereby establishing this fragment as
a critical structural constituent of the proteolytically
stable core of the PHF and not simply one of the
many proteins which can be labelled in tangles and
co-purify with PHFs in crude brain extracts [11–21]
(Fig. 1).
Since this fragment of tau accounted for 92% of
the total protein content of such preparations, it fol-
lowed that molecules of the diaminophenothiazine
type must be blocking a tau-tau binding interac-
tion that is critical for maintaining the structural and
proteolytic stability of the PHF. Pre-treatment with
a diaminophenothiazine eliminated the proteolytic
stability of the 10–12 kDa protein fragment [22].
This implied that the proteolytic stability of the PHF
core unit was not inherent to the tau molecule, but
was rather secondary to its configuration within the
assembled filament.
In order to understand the mechanism better,
we developed a relatively simple in vitro tau-tau
binding assay in which the PHF-core tau fragment
(Ile-297 - Ala-390) was first incubated in the solid
phase, and the binding of full-length recombinant
4-repeat tau added in the aqueous phase was mea-
sured immunochemically [22, 23] (Fig. 2). Three
surprising observations emerged from these studies.
The first was that binding could be blocked by the
same diaminophenothiazines found to dissolve pro-
teolytically stable PHFs isolated from AD brain [22].
The second was that after digestion of the bound
complex with Pronase, full-length tau lost its N-
terminal domain and acquired a neo-epitope detected
with mAb 6/423 which recognizes a C-terminal trun-
cation at Glu-391 present in the core of the PHF
[22, 24]. Since both species in the bound complex
lacked this epitope, its appearance after exopro-
tease digestion could only be explained as having
come from full-length tau as the proteolytically sta-
ble footprint of the tau-tau binding interaction in
the repeat domain. The third feature was that the
binding interaction could be propagated through
repeated binding/digestion cycles after addition of
fresh full-length tau at each cycle with increasing
Fig. 1. Tau composition of the PHF core. Fragmented PHFs (A), isolated from AD brain tissue, release a 10–12 kDa doublet following
extraction with formic acid (B). This doublet corresponds to fragments from the C-terminal part of tau protein that contain the repeated
tubulin-binding domain (yellow boxes) and vary depending upon the inclusion or exclusion of an additional repeat (green box) inserted in
the protein by alternative splicing (C). Scale bar in A, 200 nm.
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Fig. 2. Tau aggregation in vitro demonstrates that the tau fragment from the PHF core permits autocatalytic propagation at the expense of
normal tau. When incubated in the solid phase, the tau fragment from the core of the PHF binds full-length tau with high affinity and converts
the repeat domain from the bound full-length tau molecule into a proteolytically stable replicate of the starting fragment. In these assays, the
broad spectrum exoprotease Pronase was used [22]. A neo-epitope at the C-terminus of the newly truncated fragment recognized by mAb
6/423 (which recognizes a C-terminal truncation at position Glu-391) is created after digestion and is amplified in the course of repeated
binding/digestion cycles. The core domain is shown in a C-shaped hairpin conformation to take account of what is now known of the atomic
structure of this fragment within the PHF-core [39].
accumulation of the proteolytically stable core unit
in the solid phase [22]. Taken together, these obser-
vations implied that the tau-tau binding interaction
occurring through the repeat domain of the molecule
was responsible for both the proteolytic and struc-
tural stability of the of PHF and was inherently
auto-catalytic and self-propagating, i.e., “prion-like”
[1].
These properties were later confirmed in a sta-
ble cellular model system [25]. The core 10–12
kDa tau unit is highly toxic when overexpressed
in cells. In order to model the templated truncation
process within a cellular environment, it was neces-
sary to establish a dual expression system in cells
that do not normally express tau, namely fibroblasts.
In this system, the PHF-core tau unit is expressed
constitutively at very low non-toxic levels, and full-
length four-repeat tau is expressed under the control
of an inducible vector. Induction of full-length tau
leads to its templated conversion to the core unit
with the characteristic 10–12 kDa gel mobility. This
conversion was blocked quantitatively by the same
diaminophenothiazine-class molecules which had
been found to dissolve proteolytically stable PHFs
and which also blocked the tau-tau binding assay
modelled in a cell-free environment [25]. Therefore,
once present, the core-tau unit is able to propagate
itself at the expense of normal full-length tau within
the normal cellular milieu.
Finally, overexpression of the PHF-core tau unit
in a transgenic mouse model produced tau aggre-
gation pathology which is restricted to entorhinal
cortex and hippocampus in 3-6-month-old mice, and
spreads to isocortex only after mice are 12 months
old (Fig. 3). This pattern of spread reproduces a
characteristic feature of the tau pathology of AD
that forms the basis of the Braak staging system in
humans [27] discussed further below. A significant
cognitive deficit was present already from 3 months
of age in the absence of any motor impairment.
Amelioration of both tau aggregation pathology and
cognitive impairment were achieved following six
weeks treatment with methylthioninium (MT) [26],
the prototype diaminophenothiazine we have taken
into clinical development and which is discussed fur-
ther below.
STRUCTURE AND ASSEMBLY OF PHFS
PHFs isolated from AD brain tissue without
Pronase digestion have a fuzzy outer coat (Fig. 4A).
Although such PHFs are still recognized by mAb
6/423, they require higher concentrations of the anti-
body to do so [24]. This suggests that the N- and
C-terminally truncated repeat domain tau unit is
present within PHFs in a manner that is partially
occluded by the fuzzy coat. This interpretation was
supported by immunohistochemical studies examin-
ing the sequencing of tau aggregation and truncation
in AD brain tissues. The aggregates recognized by
mAb 6/423 are initially amorphous and are not
labelled by benzothiazole fluorophores that bind to
assembled PHFs. As these aggregates are converted
to PHFs, they acquire the ability to bind benzoth-
iazoles, but lose mAb 6/423 immunoreactivity. The
latter can be revealed by formic acid treatment of the
histological section [28].
The fuzzy coat contains the portions of the
tau molecule that are N-terminal to the repeat
domain core. Immunoreactivity associated with the
N-terminal portion of the molecule is lost after prote-
olytic removal of the fuzzy coat [8, 10]. Since the
core structure remains intact after removal of the
fuzzy coat, it can be concluded that the N-terminal
half of the tau molecule makes no contribution
to the core, which contains no post-translational
modifications [29]. The epitopes recognized by
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Fig. 3. Transgenic tau mice exhibiting both regional and age-related spread of tau immunoreactivity. Line 1 mice demonstrate a significant
age-related spread of tau-reactive cells from entorhinal cortex and hippocampus to neocortex that is reminiscent of Braak staging, and a cor-
responding increase in numbers of cells having tau pathology. A, amygdala; AC, auditory cortex; ERC, entorhinal cortex; Hip, hippocampus;
RSC, retrosplenial cortex; S, subiculum; VC, visual cortex. Source: From Melis et al., Cell Mol Life Sci 72, 2199-2222, 2015.
Fig. 4. The subunit structure of the PHF core. (A) PHFs, isolated from AD brain tissue, are surrounded by a fuzzy coat (left panel) that is
removed by proteolysis to reveal a PHF having a protease-resistant core and characteristic filamentous appearance (middle panel). Model
reconstruction (right panel) revealed a C-shaped subunit structure in transverse section (B), consistent with the atomic structure which has
been determined by cryo-electronmicroscopy of PHFs (C) [39].
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phosphate-dependent antibodies are located exclu-
sively in the fuzzy coat [30].
These complex immunochemical properties have
led to considerable confusion in the literature regard-
ing the potential role of phosphorylation of tau protein
both as a therapeutic target and as providing a con-
jectural bridge to altered process of APP in AD.
A widely quoted misconception that has remained in
the literature since 1991 [31] is that “PHFs are com-
posed almost entirely of hyperphosphorylated tau
protein”. However, the molecular mass of the PHF
core is ∼65 kDa/nm [10], or ∼6.5 × 10 kDa core tau
units per nm. Since the mass of the N-terminal half
of the tau molecule is ∼23 kDa, the predicted mass
of PHFs isolated without protease treatment would
be ∼210 kDa/nm if all of the PHF tau protein were
N-terminally intact. However, such PHFs have a max-
imal mass of 110 kDa/nm, and more typically 80–95
kDa/nm [10]. This implies that the bulk of the molec-
ular mass of the PHF is made up of truncated tau,
and only 1 in 7 tau molecules is N-terminally intact.
These approximations, based on structural data, agree
well with direct immunochemical measurements of
PHF preparations, since phosphorylated tau accounts
for less than 5% of total PHF-tau measured inde-
pendently of phosphate-dependent immunoreactivity
[7, 32]. Whether full-length hyperphosphorylated tau
protein is simply attached on the outside of the core
polymer, or whether some of the structural tau units
of the core are N-terminally intact is not known at
present. Either way, it is extremely unlikely that PHFs
could be composed “almost entirely of hyperphos-
phorylated tau protein” as widely supposed.
Systematic tau-tau binding studies in vitro using
the assay described above showed that, as the con-
centration of either truncated tau in the solid phase or
full-length tau in the aqueous phase species increases,
their respective binding affinities increase to asymp-
totic values of 21.1 ± 2.9 and 31.5 ± 22.6 nM,
respectively [33]. This implies that a conformational
change can be induced in a concentration-dependent
manner which facilitates tau-tau binding. This
concentration-dependent enhancement is not seen
in the tau-tubulin binding interaction, which has a
19-fold lower binding affinity of 403 ± 86 nM irre-
spective of tau or tubulin concentration [33].
Both tau-tau and tau-tubulin binding through
the repeat domain are profoundly disturbed by
phosphorylation. In the case of tau-tau binding, phos-
phorylation produces a 10- to 50-fold inhibition
depending on the precise configuration of the mea-
surement [33]. For tau-tubulin binding, the inhibition
is 24-fold. Therefore, phosphorylation controls the
folding of the tau molecule in solution in such a way
as to occlude the availability of the binding domain.
These findings also imply that it is unnecessary to
invoke phosphorylation as a mechanism responsible
for the transfer of tau protein from predominantly
tubulin-bound to predominantly aggregated states,
as is widely assumed [34]. Once the repeat-domain
fragment is available in a suitable conformation, the
dynamics of microtubule assembly and disassembly
will favor the redistribution of the tau protein pool to
the aggregated state simply by virtue of differential
binding affinities. The progressive accumulation of
endogenously truncated tau in AD brain suggests that
the cellular clearance mechanisms are compromised
once the repeat domain is locked in its proteolytically
stable configuration and that the aggregated truncated
form represents a kinetic sink [32]. Indeed, quantita-
tive analyses of soluble and aggregated tau in AD
brain tissues implied that the loss of soluble tau is
insufficient to explain the accumulation of aggregated
tau. Rather, it appears that the soluble tau pool is being
maintained by increased production to compensate
for loss into the aggregated form [32].
The inhibitory effect of phosphorylation can be
eliminated by first binding full-length tau to the solid
phase [33]. This removes the conformational protec-
tion afforded by phosphorylation which shields the
repeat domain from pathological aggregation. There
is some evidence supporting the idea that the critical
binding substrate which enables the initial conforma-
tional change required to trigger the tau aggregation
cascade may be related to products of incomplete
mitochondrial clearance [1, 35]. Lipofuscin deposits
which typically accumulate in aging neurons are
composed of undigested products of mitochondrial
turnover [36]. These mitochondria-derived fragments
co-localize with truncated tau in lysosomes, co-
purify with proteolytically stable PHFs and form
SDS-resistant complexes with truncated tau [22, 35].
Although such aggregates may provide the primary
substrate needed to seed tau aggregation, the process
is self-propagating and autocatalytic once initiated.
Such a scenario would then locate the initiation of
tau aggregation within the framework of a more
general age-related impairment in the efficiency of
endosomal-lysosomal processing which is required
for clearance of membrane-bound proteins (such as
APP) and mitochondria [37, 38] (Fig. 5).
A low resolution structure of the PHF core was
initially described on the basis of direct negative-
stain electron microscopy observations and model
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building [9]. Isolated PHFs are characterized by
longitudinal strands which transition between a 4-
stranded to a 3-stranded appearance in the course of
a left-hand helical rotation of an underlying ribbon-
like structure (Fig. 4A). Since the filaments have
clean transverse breaks, the underlying subunit must
be transverse in orientation. These features can be
explained by two C-shaped subunits back to back with
a core unit consisting of three distinct domains. This
structure was confirmed by image diffraction analysis
of isolated core-PHFs (Fig. 4B).
More recently, this core structure has been con-
firmed more elegantly by cryo-electronmicroscopy
which has permitted detailed resolution at the atomic
level [39]. The sequence of the repeating core tau unit,
determined structurally [39], corresponds almost
exactly to the sequence first isolated from the PHF
core 29 years ago [8]. The only difference is that the
proteolytically stable unit, shown biochemically [8,
24], extends by 8 residues N-terminal and 13 residues
C-terminal relative to the sequence that could be
visualised by cryo-electronmicroscopy (i.e., Ile-297 –
Glu-391, rather than Val-306 – Phe-378). The atomic
resolution structure has made it possible to see for
the first time that this core tau unit is arranged as
a bent hairpin structure arranged to produce the C-
shaped structural subunit (Fig. 4C). We have recently
found that the core tau expressed in vitro unit exists
in two distinct conformations with gel mobilities of
10- and 12-kDa, respectively [40]. Only the 12-kDa
form is assembly competent, and assembles sponta-
neously into double helical ribbons with the same
4-stranded to 3-stranded transitions that indicate the
presence of the same C-shaped subunit originally
seen in PHFs. This suggests that the bent hairpin
configuration of the repeat domain can occur in solu-
tion, that the bonds maintaining it are SDS-resistant
even in the monomeric form, and that this critical
conformational transition can occur in the absence
of any post-translational modification [40]. In par-
ticular, these studies exclude any requirement for
formation of disulphide cross-links in PHF assembly.
These structural findings have important impli-
cations for understanding exactly how diaminophe-
nothiazines are able to disassemble the PHF core
and reverse the proteolytic stability of the repeat
domain in its assembly-competent configuration [22].
It has been known for some time that the tau-tau
and tau-tubulin binding interactions are pharmaco-
logically distinct, even though both occur through the
repeat domain [22]. Using MT as the prototype com-
pound, dissolution of PHFs isolated from AD brain
can be demonstrated at MT concentrations approxi-
mately 1/10th that of the PHFs [25]. This makes it
unlikely that the action of MT is competitive, but
rather suggests a catalytic interaction of some kind.
It is tempting to speculate that MT works by de-
stabilizing the hairpin configuration of the of the core
tau unit which makes it assembly-competent. This
would result in reversion of the core tau unit into a
form which is both assembly-incompetent and more
susceptible to proteolytic pathways available for pro-
tein clearance [41]. In the cell model described above,
which is an inherently dynamic system, the levels of
the core tau unit relative to full-length tau are reduced
after treatment with diaminophenothiazines, imply-
ing both inhibition of tau aggregation and enhanced
clearance of tau aggregates. That is, the core tau unit is
no longer kinetically trapped in the aggregated state in
the presence of diaminophenothiazines. Interestingly,
MT enhances autophagy and clearance of aggregated
tau protein in a transgenic mouse model at 0.05M
[42] and, at low dose, induces genes regulated by
NF-E2-related factor 2 (Nrf2) which control path-
ways available for clearance of proteotoxic proteins
in another transgenic tauopathy mouse model [43].
How these effects are related to dissolution of tau
aggregates is unknown, but both point to enhance-
ment of the ability of neurons to clear them.
POTENTIAL CLINICAL EFFICACY OF
TAU PROTEIN AGGREGATION
INHIBITOR THERAPY IN AD
Although MT has attractive properties in vitro and
in transgenic mouse models as a possible treatment
for the tau pathology of AD, its clinical pharmacology
is complex. This is due in part to the redox labil-
ity of the molecule at physiological pH values. The
best studied example is in the treatment of methe-
moglobinemia which is the only approved clinical
indication for the use of MT. When the MT moiety
is administered intravenously in its oxidized form
(MT+) as methylthioninium chloride (MTC, com-
monly known as “methylene blue”) it needs first to
be reduced to its uncharged form (LMT for “leuco-
MT”) to permit it to cross the red cell membrane [44]
(Fig. 6). It is then concentrated inside the cell as a
result of an equilibrium between the oxidized form
which is favored at physiological pH and the reduced
form which is maintained in an energy-dependent
fashion by consumption of reduced glutathione [44].
This dynamic equilibrium permits MT to transfer
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Fig. 5. Involvement of the endosomal–lysosomal pathway in removal of aggregated proteins. Congestion of the clearance pathway associated
with progressive age-related failure of normal mitochondrial turnover leads to release of products of failed clearance which become seeds for
triggering tau aggregation. The resulting tau oligomers add to congestion in the pathway and themselves catalyze further tau aggregation. The
tau aggregation cascade proceeds by an autocatalytic process of binding and proteolysis of tau, initiated through its capture of by-products of
failed mitochondrial clearance resulting from age-related failure of endosomal–lysosomal processing. Source: From Wischik et al., Biochem
Pharmacol 88, 529–539, 2014.
electrons to oxidized hemoglobin thereby reducing
it. A similar electron shuttling mechanism is thought
to underlie the ability of MT to enhance mitochon-
drial metabolism [45]. It is not known whether this
redox lability is critical either for dissolution of PHFs
or preventing tau aggregation.
The first tau protein aggregation inhibitor (TAI)
to enter clinical development was MT in its oxi-
dized MT+ form as MTC. As indicated above, MTC
has a long history of safe use, both as an approved
treatment for methemoglobinemia [46], and experi-
mentally in urolithiasis and bipolar disorder amongst
others [47–49]. A phase II clinical trial was con-
ducted between 2004–2008 in 321 subjects with
mild/moderate AD [50] The trial was designed as
an exploratory double-blind, randomized, placebo-
controlled, 24-week dose-finding study of MT as
monotherapy in AD to test the doses 69, 138 and
218 mg day given in divided doses three times per day
on clinical and functional brain imaging (HMPAO-
SPECT) outcomes.
The primary efficacy analysis at 24 weeks showed
that treatment with MT 138 mg/day is the minimum
effective dose required to prevent disease progression
when given as MTC. In the pre-specified primary effi-
cacy analysis, treatment with 138 mg/day produced
statistically significant benefit with respect to placebo
on the ADAS-cog scale (effect size = –5.42 units,
CI = [–9.44, –1.41], nominal p = 0.008, corrected
p = 0.047) at 24 weeks in patients with moderate
AD at baseline. Significant effects were also seen
on the secondary outcome scales Alzheimer’s Dis-
ease Cooperative Study - Clinical Global Impression
of Change (ADCS-CGIC) and Mini-Mental State
Exam (MMSE) (effect size = 3.79 units, CI = [1.16,
6.41], nominal p = 0.0048, corrected p = 0.028). A
significant treatment effect was also seen at the same
dose on the functional molecular imaging outcome
(HMPAO-SPECT) in a separate population (mild
subjects) at 24 weeks (effect size = 1.97%, CI = [1.02,
2.92], nominal p < 0.001, corrected p < 0.001). Over
50 weeks, clinical benefit was seen in both mild
and moderate AD (effect size = –3.80 Alzheimer’s
Disease Assessment Scale–cognitive (ADAS-cog)
units, CI = [–3.31, –3.25], nominal p = 0.004, cor-
rected p = 0.011).
Surprisingly, a higher dose of 228 mg-MT/day was
less effective on both clinical and functional imaging
outcomes [50]. This was found to be due to dose-
dependent impairment in absorption in the presence
of food [51]. As indicated above, the oxidized MT+
needs to be reduced to the uncharged LMT form to
permit absorption. This was confirmed in vivo by
the observation that the red cell uptake of the LMT
form is 20-fold better than the MT+ form [51]. Red
cell uptake is important for distribution of MT to the
brain, since this sequestration protects the molecule
from an efficient first-pass metabolism which inac-
tivates MT as a tau aggregation inhibitor [51]. The
conversion from the MT+ form to the LMT form,
which is favored at low pH values [52], most likely
occurs in the stomach and is impaired in the presence
of food. The further clinical development of the MT
moiety in Phase 3 was therefore switched to a sta-
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ble reduced dosage form as leuco-methylthioninium
bis(hydromethanesulfonate) (LMTM). LMTM is a
distinct novel chemical entity which retains tau aggre-
gation inhibitor activity in vitro and in vivo [25,
26], has superior pharmaceutic properties in terms
of solubility and pKa, and is not subject to the
absorption limitations of the MT+ form as MTC [51]
(Fig. 7).
LMTM was tested in two Phase 3 randomized con-
trolled double-blind clinical trials in AD. The first
(TRx-237-015, “Study 015”) was a 15-month study in
891 patients with mild to moderate AD and compared
150 mg/day and 250 mg/day with a low dose intended
as a control (8 mg/day) in divided doses twice per day
[53]. The second (TRx-237-005, “Study 005”) was
an 18-month study in 800 patients with mild AD and
compared 200 mg/day with the same intended con-
trol in divided doses twice per day. The control dose
of 8 mg/day was selected as the lowest dose found to
be able to mask urine discoloration relative to higher
doses in earlier Phase 1 studies, and was expected to
be ineffective on the basis of the results of the earlier
Phase 2 study using MTC. In addition to having an
active control arm, the Phase 3 studies also differed
from the earlier Phase II study in permitting LMTM
to be taken as add-on to approved anti-dementia treat-
ments (cholinesterase inhibitors and/or memantine),
whereas the Phase 2 study did not.
In Study 015, it was shown that there was no
difference between either of the two higher doses
Fig. 6. Cellular uptake of methylthioninium species. A model to explain the complex absorption characteristics of MT leading to differential
disposition of LMT and MTC. Source: From Baddeley et al., J Pharmacol Exp Ther 352, 110-118, 2015.
Fig. 7. Structures of the diaminophenothiazines MTC and LMTM. Methylthioninium is a diaminophenothiazine which exists in a redox
equilibrium between oxidized and reduced forms, represented here as MTC and LMTM (A, B), respectively. The X-ray crystal structures of
the molecules shown below each form are distinct from each other (C, D); the nitrogen atoms are planar in the case of MTC and tetrahedral
for LMTM (red arrows). The geometry of the nitrogen atoms contributes to the stability of LMTM in an oxygen atmosphere in its crystalline
form as the dihydromesylate salt.
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and the intended control dose on either of the co-
primary outcomes (ADAS-cog and ADCS-ADL) or
any of the secondary outcomes [53]. However, the
primary prespecified analysis model showed that
patients who received LMTM as monotherapy had
a lower rate of progression (ADAS-cog, p < 0.0001;
ADCS-ADL, p = 0.0174; ADCS-CGIC, p < 0.0001;
MMSE, p < 0.0001). A further prespecified post hoc
analysis was therefore undertaken in the whole popu-
lation which included anti-dementia treatment status
as an interaction term with LMTM treatment and
as an interaction term with visit in the model. In
patients taking LMTM as monotherapy, the differ-
ences with respect to the control arm were significant
after correction for multiple comparisons on all treat-
ment outcomes. For ADAS-cog, the effect size at
150 mg/day was –6.25 units (CI = [–8.92, –3.59],
nominal p < 0.001) and for 250 mg/day was –5.79
units (CI = [–8.47, –3.11], nominal p < 0.001). For
ADCS-ADL, the effect size at 150 mg/day was 6.48
units (CI = [2.87, 10.09], nominal p = 0.001) and for
250 mg/day was 6.93 units (CI = [3.29, 10.57], nom-
inal p < 0.001). Similar results were seen for other
clinical outcomes, and importantly the rate of brain
atrophy was significantly less in the monotherapy
patients. In patients taking the same doses of LMTM
as add-on to approved anti-dementia treatments, the
decline was indistinguishable from controls as ran-
domized or from placebo controls in recently reported
studies [54, 55].
When the control arm was analyzed in simi-
lar manner, patients receiving LMTM 8 mg/day as
monotherapy also had significantly better outcomes
than those receiving the same dose as add-on to
approved anti-dementia treatments. For ADAS-cog,
the difference between 8 mg/day as monotherapy rel-
ative to add-on was –5.90 units (CI = [–8.13, –3.66],
nominalp < 0.001). For ADCS-ADL, the correspond-
ing difference was 7.19 units (CI = [4.19, 10.23],
nominal p < 0.001).
These differences between monotherapy and add-
on could not be explained by differences in age or
sex distribution, in baseline ADAS-cog or MMSE
scores, or time between diagnosis and randomiza-
tion. Patients with mild (but not moderate) AD who
were not taking these medications were marginally
worse on the ADCS-ADL scale, had a slightly greater
hippocampal volume and smaller lateral ventricular
volume on baseline MRI, and had a lower APOE 4
allele carrier frequency. There were no differences
in mild or moderate patients in whole brain volume,
temporoparietal volume, or in the extent of vascu-
lar pathology burden. There was also no difference
in the initial rate of expansion of lateral ventricular
volume over the first 6 months. When the differ-
ences in baseline severity, hippocampal volume, and
other parameters were corrected for, the differences
in favor of monotherapy remained statistically signif-
icant (Fig. 8).
The results of Study 015, which became available
prior to database lock and unblinding of Study 005,
raised the possibility that LMTM might be effective
only as monotherapy and that the minimum effec-
tive dose might be substantially lower for LMTM
than that previously identified using MTC [50].
Since the originally intended analyses as randomized
were unlikely to be able to achieve their intended
purpose, the primary analyses and treatment compar-
isons in the statistical analysis plan for Study 005
were modified prior to database lock and unblinding
to investigate whether the monotherapy differences
could be confirmed as observational cohort com-
parisons defined as primary outcomes with strong
control of family-wise type I error in the second inde-
pendent study. The monotherapy cohort comparisons
which were of particular interest in light of the earlier
study were: 100 mg twice a day as monotherapy com-
pared with 4 mg twice a day as originally randomized,
and 4 mg twice a day as monotherapy compared with
4 mg twice a day as add-on to standard AD treatments.
These were defined as two parallel primary compar-
isons which each had to be significant at = 0.025
for the analysis to be successful. The results of Study
005 have been reported recently [56]. As expected,
there was no evidence of any difference on any of the
primary or secondary endpoints in the as-randomized
analyses comparing all patients receiving LMTM at a
dose of 100 mg twice a day and those receiving 4 mg
twice a day. In the non-randomized cohort compar-
isons defined as the primary outcomes in the revised
statistical analysis plan, both primary comparisons
were statistically significant for both co-primary clin-
ical outcomes (ADAS-cog and ADCS-ADL), as well
as for volumetric MRI and glucose uptake (FDG-
PET) biomarker outcomes. Patients receiving LMTM
as monotherapy at either of the two doses tested had
consistently better outcomes than patients receiving
the same doses as add-on to anti-dementia treatments.
These effects remained significant after correction
for any potential effects of differences at baseline in
patients taking or not taking approved anti-dementia
treatments.
The confirmation of the same pattern of results in
the second independent study argues against either set
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Fig. 8. Change from baseline in ADAS-cog and ADCS-ADL for Study 015. The results are shown for the as-randomized primary analysis
with AD co-medication status as an additive term in the model (A1, B1), or prespecified repeat of primary analysis with AD-co-medication
status as an interaction term in the model showing effect of LMTM treatment as either monotherapy or as add-on to existing AD treatments
(A2, B2). A post-hoc analysis is shown for low dose (8 mg/day) with LMTM given as monotherapy or as add-on (A3, B3). ns, not significant.
Source: Adapted from Gauthier et al., Lancet 388, 2873-2884, 2016, with permission of Elsevier.
of findings being the result of chance in small sub-
groups, although the monotherapy subgroups remain
small (15% and 20% in Studies 015 and 005, respec-
tively). It is also unlikely that the earlier findings
are explicable by inclusion of non-western geogra-
phies, since the second study was conducted in north
America, western Europe, and Australia. A clinical
placebo effect in patients coming into a trial setting
after previously not receiving active treatment cannot
explain the same pattern of results seen in both the
MRI brain atrophy and glucose uptake data as seen
in the clinical data. A difference in withdrawal rates
between patients taking or not taking standard AD
treatments is also unlikely, since the overall retention
rates over 18 months were similar in monotherapy
(65%) and add-on (69%) treatment groups in Study
005. The pattern of atrophy determined by MRI at
baseline in patients receiving LMTM as monother-
apy was typical of mild AD and significantly different
from a cohort of well characterized normal elderly
controls [57]. The annualized rate of whole brain atro-
phy in these patients over the first 6 months was also
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Fig. 9. Molecular changes in neocortex by Braak staging. Proteolytically stable PHFs are present in neocortex from Braak stage 2 onwards
(A); levels of SNAP-25 (as well as synaptophysin and syntaxin, not shown) increase significantly at Braak stage 3 and decline only after
Braak stage 5 (B); significant numbers of neurofibrillary tangles are not observed until Braak stage 4 and beyond (C). Measures determined
for frontal and temporal cortices. Source: Adapted from Mukaetova-Ladinska et al., Am J Pathol 157, 623-636, 2000, with permission of
Elsevier.
similar to that reported for mild AD and significantly
different from normal elderly controls [58]. Likewise
glucose uptake in inferior temporal gyrus was compa-
rable in both monotherapy and add-on patients to that
reported for mild AD [59] and significantly different
from MCI or normal elderly controls [59]. There is no
reason, therefore, to assume that patients not treated
with approved AD treatments were anything other
than typical mild AD patients. When the analyses
were corrected for potential differences in baseline
severity and a range of other baseline parameters, the
results again remained robustly significant.
The potential for LMTM to be active at the low
dose of 8 mg/day and the lack of dose-response was
unexpected given the results of an earlier Phase II
placebo-controlled study using MTC. However, as
indicated, LMTM is now known to have a 20-fold
better red cell uptake than MTC in vivo [51] and also
better brain uptake [26]. A population pharmacoki-
netic analysis using blood samples collected in the
course of the second study indicate that the higher
dose produced higher plasma levels of MT. Using
data from rat and pig to estimate brain levels from the
plasma data obtained in the trial, the estimated brain
concentration of MT at the 8 mg/day dose was in the
range 0.05–0.2M and 2.0–3.8M at the 100 mg
twice a day dose. The brain concentration estimated
at the 8 mg/day dose is similar to the minimum effec-
tive concentration estimated from the earlier Phase II
clinical trial using MTC [50, 51]. Although this dif-
ference in dosage requirement between LMTM and
MTC is consistent with the 20-fold difference in cell
uptake, this was not known at the time the Phase III
studies were designed and initiated. The lack of dose-
response may well be explained by a similar lack of
dose-response for oligomer disaggregation in vitro,
and higher doses of LMTM do not result in greater
reduction in tau pathology in transgenic mouse mod-
els [26]. This suggests that there may be a critical
threshold for the catalytic action of MT in the disso-
lution of PHFs and oligomers, and the effect of higher
doses on pathology may plateau or may even become
negative at brain concentrations above 1M [26]. A
similar inverse dose-response was also found in a dif-
ferent transgenic model of tau aggregation pathology
in which mice received MTC in the drinking water
from 1–9 months of age [43].
The negative interaction with symptomatic anti-
dementia treatments is more difficult to explain. We
have recently found that the interference is not all-or-
none, but depends in part on relative basal forebrain
atrophy. Our current working hypothesis is that long-
term inhibition of cholinesterase activity (or indirect
enhancement of cholinergic activity by memantine)
combined with loss of inhibitory modulation from the
basal forebrain may result in chronic hyperactivation
of pyramidal cells in cortex which are the principal
sites of neurofibrillary degeneration in AD [60]. We
hypothesize that hyperactivation of cortical pyrami-
dal cells may impair the action of MT even at high
dose. It is unknown whether interference of this type
is a feature of any treatment aiming to enhance clear-
ance of aggregated tau, or whether it is specific to
LMTM.
As a clinical summary, therefore, the same pattern
of results has been seen now in two separate Phase III
studies implying that the effects are consistent across
studies. They are also internally consistent across a
range of clinical and biomarker outcomes. Allowing
for the differences in absorption between LMTM and
MTC which are now known, the results are also con-
sistent with the earlier Phase II placebo-controlled
study supporting potential efficacy of the MT moi-
ety as monotherapy. We believe that the within- and
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between-study consistency of the results point to clin-
ical and biological effects of LMTM as monotherapy
at the safe and well-tolerated dose of 8 mg/day twice
a day which could provide a clinically meaningful
addition to the available treatment options for AD.
This possibility now needs to be confirmed in a fur-
ther suitably randomized clinical trial in patients not
currently receiving the approved anti-dementia treat-
ments. Although the apparent treatment differences
in favor of monotherapy do not appear to be the
result of measurable differences between the cohorts,
it is impossible to exclude unmeasured confounding
effects without a further randomized trial comparing
8 mg/day against true placebo.
LIFE-COURSE AND PREVALENCE OF
TAU PROTEIN AGGREGATION
The potential for availability in the near future of a
safe tau aggregation inhibitor therapy as monotherapy
needs to be considered in the context of the life-
course and prevalence of tau aggregation pathology.
Numerous clinico-pathological studies have demon-
strated correlations between tau pathology and the
extent of clinical dementia [61–70]. The staging sys-
tem for spread of tau aggregation pathology proposed
by Braak and Braak [27] has proved a valuable tool
in refining these correlations and understanding the
prevalence of the process.
The pattern of spread of the tau aggregation pathol-
ogy in the human brain is highly characteristic and
stereotyped. Layer II of entorhinal cortex is the first
area to be affected in cortex, although there may
be earlier involvement in basal forebrain and brain-
stem structures [2, 71]. We reported a study in a
prospectively characterized neuropathological cohort
in which we examined the sequence of changes in
tau aggregation measured biochemically (as prote-
olytically stable PHF-tau levels) and corresponding
changes in synaptic markers occurring in neocor-
tex [68]. The Braak staging “clock” can be defined, at
the early stages, on the basis of the pattern of spread
of histopathological changes restricted largely to
entorhinal cortex and hippocampus (stages 1–3). The
sequence of changes in parietal and frontal neocortex,
which begin later in terms of histopathology (stages
4–6), can then be analyzed at the molecular level as
they develop against an initially clear histopatholog-
ical background, using the Braak staging clock to
order the sequence. These are summarized in Fig. 9.
In contrast to tau histopathology (measured as tan-
gle counts) which becomes apparent in neocortex
only from Braak stage 4 onwards, accumulation of
proteolytically stable PHFs in the neocortex is already
significant from Braak stage 2. In the neocortex,
therefore, tangles are a relatively late manifestation
of tau aggregation pathology. The calculated interval
between onset of tau aggregation in neocortex and
tangle histopathology is about 35 years. Braak stages
4 – 6 represent the more typically recognized stages of
pathology, in which the appearance of tau tangles and
tau-positive, neuritic plaques occurs at approximately
the same time. Braak stage 4 is a point of neuropatho-
logical transition that is expressed simultaneously as
neurofibrillary tangles and neuritic/amyloid plaques.
Further progression in Braak stages 5 and 6 is seen
only for the tau and synaptic markers.
It is surprising to see that the changes in levels
of synaptic proteins measured biochemically in the
same brain regions follow a biphasic course, with an
initial increase at Braak stage 3, followed by progres-
sive decrease from Braak stage 4 onwards [68]. This
implies that the appearance of measurable levels of
proteolytically stable aggregated tau in the neocortex
at Braak stage 2 is followed by a statistically signifi-
cant increase in synaptic proteins at Braak stage 3. It
is not known whether this increase is a compensatory
consequence of a functional impairment in pyrami-
dal transmission, or whether it represents a release
phenomenon resulting in loss of inhibition resulting
from basal forebrain atrophy where tau aggregation
pathology is known to occur early in the sequence.
Either way, the increase in synaptic markers sug-
gests hyperactivation which may be accentuated by
chronic treatment with cholinesterase inhibitors and
memantine, as discussed earlier.
Cognitive impairment in this epidemiological
cohort was studied using MMSE scores obtained
12–24 months prior to death. From this, it was possi-
ble to derive an approximate trajectory linking Braak
stage and MMSE score [68] (Fig. 10A). What is now
referred to interchangeably as prodromal AD or mild
cognitive impairment (i.e., MMSE score >25) occurs
roughly between Braak stages 2 and 3. There are
similar strong relationships between Braak stage and
functional molecular imaging deficits as shown either
by HMPAO-SPECT or FDG-PET which have similar
ability to demonstrate deficits due to neuropathology
[72, 73]. Both HMPAO-SPECT [74, 75] and FDG-
PET [76] are correlated with Braak stage (Fig. 10B).
The emergence of tau imaging ligands has made pos-
sible the direct imaging of tau aggregation pathology
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Fig. 10. Correlation of Braak staging with cognitive decline and pathology. Cognitive decline is measured by MMSE determined 12–24
months antemortem and tau pathology measured in vivo using 18F-AV-1451 (tau) PET. Source: (A) From Wischik et al., Biochem Pharmacol
88, 529-539, 2014; (B) From Scho¨ll et al., Neuron 89, 971-982, 2016, with permission of Elsevier.
Fig. 11. Time course of accumulation of aggregated PHF-tau in AD and associated cognitive decline on the MMSE scale.
in vivo [77, 78]. This has permitted an explicit confir-
mation of the relationship between aggregation of tau
and functional molecular imaging deficits. Functional
deficit is strongly correlated with tau aggregation
as shown by tau-PET imaging, but not with aggre-
gation of amyloid- as shown by imaging with
11C-PIB [79, 80].
Data coming from several clinico-pathological
correlation studies are summarized in Fig. 11 show-
ing the evolution of tau aggregation over time in
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Fig. 12. Age-associated probability of transition from an earlier to a later Braak stage (“BS”) (A) applied to estimate number of persons (in
millions) worldwide at a given Braak stage in 2015 and their predicted age distribution (B).
archicortex and neocortex and the relationship to cog-
nitive decline [7, 68, 81]. As can be seen, the entire
sequence occurs over a 50-year time-span. The pri-
mary vertical axis shows levels of aggregated tau in
the form of proteolytically stable PHFs measured
in entorhinal cortex, hippocampus, and neocortex
on a logarithmic scale. The progressive accumu-
lation of aggregated tau is exponential over time,
consistent with the autocatalytic characteristics of
tau aggregation through the repeat domain discussed
earlier. There is no evidence of abrupt transition
between tau aggregation in medial temporal lobe
structures and neocortex, except that aggregation in
neocortex lags aggregation in entorhinal cortex and
hippocampus.
An extremely useful data set from Ohm et al.
[82] makes it possible to estimate population preva-
lence of tau aggregation pathology by Braak stage
in Caucasian populations. We have applied the
age-dependent Braak stage transition probabilities
derived from this data set (Fig. 12A) to estimate
the number of affected persons worldwide in 2015
using WHO data (Fig. 12B). For this purpose, we
assume that the Ohm et al. data might be appli-
cable also in Asian populations, although there is
at present no evidence to support this, except that
age-related prevalence of dementia appears to be sim-
ilar [83]. We calculate that for the population over
the age of 45, there is a 50% probability of having
some degree of tau pathology in the brain. This can
be divided as follows: 25% at Braak stage 1, 10%
at Braak stage 2, 10% at Braak stage 3, and 5%
at Braak stage 4 or beyond. We estimate therefore
that there may well be almost 500 million people
worldwide with tau aggregation at Braak stage 2 or
beyond in their brains. The transition to Braak stage
2 and beyond is associated with significant impair-
ment that can be measured even on the crude MMSE
scale (Fig. 10). Of the people we estimate to be
affected, only 12% would be in Europe or North
America. Asia would account for an estimated 60% of
the affected population. There is therefore an urgent
need to develop an effective oral treatment for tau
aggregation pathology that is convenient, safe and
well-tolerated. If the results seen in two Phase 3
trials are confirmed in a further placebo-controlled
trial, they point to the potential for LMTM to fulfil
this need.
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